Seer (company)
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 2017 |
| Founder | Omid Farokhzad, Philip Ma, Robert Langer |
| Headquarters | Redwood City , United States |
Area served | North America, Europe, Asia |
Key people | Philip Ma (CEO) |
| Products | Proteograph Product Suite (Proteograph ONE Assay, SP200 Automation Instrument, Proteograph Analysis Suite) |
Number of employees | 140 (2024) |
| Website | seer |
Seer, Inc. (NASDAQ: SEER) is a biotechnology firm headquartered in Redwood City, California, specializing in cutting-edge proteomics technologies. Established in 2017, the company focuses on advancing tools for proteomic research.
History
Founded in 2017 by Omid Farokhzad, Philip Ma, and Robert Langer, Seer originated from nanoparticle innovations developed in Farokhzad’s laboratory at Brigham and Women’s Hospital affiliated with Harvard Medical School. Initial funding came from investors such as Maverick Capital, aMoon Fund, Wing VC, T. Rowe Price, and Fidelity.
In September 2020, Seer created PrognomiQ as a separate entity dedicated to clinical applications like liquid biopsy assays for early lung cancer detection. Philip Ma assumed the role of CEO at PrognomiQ, with Farokhzad serving as board chairman; Seer maintains a nearly 19% stake in the spin-off.
Seer’s initial public offering occurred on December 4, 2020, generating approximately $336.2 million in capital. The IPO was managed by underwriters including J.P. Morgan, Morgan Stanley, Bank of America Securities, and Cowen.
January 2021 marked the debut of the Proteograph Product Suite, which introduced the SP100 automation platform alongside the Proteograph RISE assay kit. In June 2023, the company launched the Proteograph XT assay kit to enhance throughput capacity by 150%.
By May 2025, Seer released an upgraded high-throughput version of its Proteograph Product Suite featuring the Proteograph ONE Assay and SP200 Automation Instrument. This system supports processing up to 1,000 samples per week to facilitate expansive proteomic investigations.
Business model and operations
Seer’s revenue streams derive from product sales targeted at government agencies, academic institutions, biopharmaceutical companies, and contract research organizations (CROs). Additionally, it provides proteomics services through its Seer Technology Access Center (STAC) facilities located in Redwood City and Bonn, Germany.
The organization employs approximately 140 personnel specializing in sales and customer support across regions including North America, Europe, and Asia. Its main headquarters and research laboratories are situated in Redwood City, California; supplementary offices exist in San Diego along with a service laboratory based in Bonn. For the fiscal year 2024, Seer reported revenues totaling $14.2 million.
Technology and product offerings
Seer’s proteomics platform integrates custom-engineered nanoparticles with automated sample preparation and mass spectrometry analysis. By employing nanoparticles that vary in size, charge, and hydrophobicity characteristics, the platform selectively enriches proteins from complex biological matrices—addressing challenges posed by wide dynamic ranges. This approach facilitates comprehensive and unbiased proteomic profiling capable of detecting proteins linked to diseases or therapeutic interventions without prior targeting assumptions.
Research published in Nature Communications in 2020 demonstrated that these nanoparticles generate unique protein coronas enabling detailed plasma proteome characterization. Independent evaluations have shown that workflows based on nanoparticle technology identify three to six times more proteins and achieve twice the reproducibility relative to conventional neat-plasma methodologies.
As of 2025, a total of 58 scientific publications have featured data generated using the Proteograph platform within prominent journals such as Nature, Nature Communications, Nature Aging, and Cell Metabolism. A notable study published in Nature Aging in 2025 reported identification of over 10,000 proteins underscoring the platform’s scalability and analytical depth.
The Proteograph Product Suite consists of three main components: the Proteograph ONE Assay—a multiplexed nanoparticle reagent system designed for protein capture; the SP200 Automation Instrument—a robotic fluid handling device optimized for high-volume sample preparation; and the Proteograph Analysis Suite (PAS)—a cloud-based software solution for processing large-scale proteomics datasets.
Partnerships
In November 2024, the company entered into a collaborative marketing and sales partnership with Thermo Fisher Scientific to advance the integration of Seer’s Proteograph technology with Thermo Fisher’s Orbitrap mass spectrometry instruments.
By June 2025, Seer had established a collaboration with Korea University and prominent Korean cancer institutions, such as Seoul National University Hospital and Samsung Medical Center, to facilitate a comprehensive plasma proteomics research project. This partnership focuses on discovering blood-based cancer biomarkers in young adults by employing Seer’s Proteograph platform in conjunction with Thermo Fisher Scientific mass spectrometers to examine more than 20,000 plasma samples.